Literature DB >> 34160085

Process and procedural adjustments to improve CD34+ collection efficiency of hematopoietic progenitor cell collections in sickle cell disease.

Scott T Avecilla1, Farid Boulad2, Karina Yazdanbakhsh3, Michel Sadelain4, Patricia A Shi5.   

Abstract

BACKGROUND: Adequate CD34+ collection efficiency (CE) is critical to achieve target CD34+ cell doses in hematopoietic progenitor cell (HPC) collections. Autologous HPC collection in sickle cell disease (SCD) is associated with unstable collection interfaces and low CD34+ CEs. We hypothesized that variables specific to SCD, activation of blood cells and elevated viscosity, might contribute to these issues and made adjustments to the collection process and procedure to address our hypothesis. STUDY DESIGN AND METHODS: In two patients with SCD undergoing autologous HPC collection on our clinical trial (NCT02193191), we therefore implemented adjustments to the process and procedure in the following areas: proximity of RBC exchange to HPC collection, the type of anticoagulation, and the packing factor setting.
RESULTS: There was no collection interface instability. Our CD34+ CE1s were high at 70% and 51%, and granulocyte CE, platelet CE, and product granulocyte % were remarkably low. Product hematocrits were not as high as previously reported to be required to obtain adequate CEs. Interestingly, one HPC product showed a hemoglobin S (HbS) of 91% at the same time that the peripheral blood (PB) showed a HbS of 22%. DISCUSSION: Adjustments to the HPC collection process and procedure were associated with adequate CD34+ CEs and low granulocyte and platelet contamination in HPC products from SCD patients. Given the discrepancy in the percentage of sickle RBCs in the product versus the PB, we hypothesize that CD34+ cells and RBCs may aggregate. Our interventions and hypothesis should be further investigated in larger studies.
© 2021 AABB.

Entities:  

Keywords:  cellular therapy; hematology-red cells; transplantation-stem cell

Mesh:

Substances:

Year:  2021        PMID: 34160085      PMCID: PMC9164294          DOI: 10.1111/trf.16551

Source DB:  PubMed          Journal:  Transfusion        ISSN: 0041-1132            Impact factor:   3.337


  36 in total

1.  Reduction of painful vaso-occlusive crisis of sickle cell anaemia by tinzaparin in a double-blind randomized trial.

Authors:  Mohamad Hasan Qari; Soad Khalil Aljaouni; Mohamad Salleh Alardawi; Huda Fatani; Fatin Mohamad Alsayes; Panagiotis Zografos; Mohamad Alsaigh; Adnan Alalfi; Mohamad Alamin; Abdulilah Gadi; Shaker A Mousa
Journal:  Thromb Haemost       Date:  2007-08       Impact factor: 5.249

Review 2.  How do I perform hematopoietic progenitor cell selection?

Authors:  Scott T Avecilla; Cheryl Goss; Sharon Bleau; Jo-Ann Tonon; Richard C Meagher
Journal:  Transfusion       Date:  2016-02-25       Impact factor: 3.157

3.  Not simply misshapen red cells: multimolecular and cellular events in sickle vaso-occlusion.

Authors:  Gregory M Vercellotti; John D Belcher
Journal:  J Clin Invest       Date:  2014-03-18       Impact factor: 14.808

4.  Bone marrow characterization in sickle cell disease: inflammation and stress erythropoiesis lead to suboptimal CD34 recovery.

Authors:  Alexis Leonard; Aylin Bonifacino; Venina M Dominical; Min Luo; Juan J Haro-Mora; Selami Demirci; Naoya Uchida; Francis J Pierciey; John F Tisdale
Journal:  Br J Haematol       Date:  2019-04-10       Impact factor: 6.998

5.  Continuous CD34+ cell collection by a new device is safe and more efficient than by a standard collection procedure: results of a two-center, crossover, randomized trial.

Authors:  Jose A Cancelas; Edward P Scott; Jerome R Bill
Journal:  Transfusion       Date:  2016-09-02       Impact factor: 3.157

6.  Automated RBC Exchange has a greater effect on whole blood viscosity than manual whole blood exchange in adult patients with sickle cell disease.

Authors:  Nassim Ait Abdallah; Philippe Connes; Gaetana Di Liberto; Lucile Offredo; Jean Louis Beaumont; Dehbia Menouche; Karima Debbache; Amna Jebali; Anoosha Habibi; France Pirenne; Frédéric Galacteros; Brigitte Ranque; Pablo Bartolucci
Journal:  Vox Sang       Date:  2020-09-23       Impact factor: 2.144

Review 7.  Optimizing leukapheresis product yield and purity for blood cell-based gene and immune effector cell therapy.

Authors:  Patricia A Shi
Journal:  Curr Opin Hematol       Date:  2020-11       Impact factor: 3.284

8.  Erythrocytes in sickle cell anemia are heterogeneous in their rheological and hemodynamic characteristics.

Authors:  D K Kaul; M E Fabry; P Windisch; S Baez; R L Nagel
Journal:  J Clin Invest       Date:  1983-07       Impact factor: 14.808

9.  Disease severity impacts plerixafor-mobilized stem cell collection in patients with sickle cell disease.

Authors:  Alexis Leonard; Akshay Sharma; Naoya Uchida; David Stroncek; Sandhya R Panch; Kamille West; Eoghan Molloy; Thomas E Hughes; Sara Hauffe; Tiffani Taylor; Courtney Fitzhugh; Jane S Hankins; Megan Wilson; Shengdar Q Tsai; Mitchell J Weiss; Matthew Hsieh; John F Tisdale
Journal:  Blood Adv       Date:  2021-05-11

10.  Neutrophil ageing is regulated by the microbiome.

Authors:  Dachuan Zhang; Grace Chen; Deepa Manwani; Arthur Mortha; Chunliang Xu; Jeremiah J Faith; Robert D Burk; Yuya Kunisaki; Jung-Eun Jang; Christoph Scheiermann; Miriam Merad; Paul S Frenette
Journal:  Nature       Date:  2015-09-16       Impact factor: 49.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.